Kyprolis® approved in Europe for relapsed myeloma patients

The European Commission has approved the use of Kyprolis (carfilzomib) in combination with Revlimid┬« and dexamethasone as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. This follows the recent recommendation by the European Medicines Agency (EMA) based on the pivotal ASPIRE trial which showed that Kyprolis in…

Details